Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:03 AM
Ignite Modification Date:
2025-12-25 @ 4:03 AM
NCT ID:
NCT01099202
Eligibility Criteria:
Inclusion Criteria:
1. Patients with a diagnosis of ALL, LL, or Burkitt's receiving induction chemotherapy with Hyper-CVAD, any variant of Hyper-CVAD or augmented BFM at MD Anderson Cancer Center.
2. Patients must be enrolled on the study + / - (plus or minus) 14 days from the start of induction chemotherapy.
3. Patients with relapsed ALL, LL, or Burkitt's are eligible, but must have had a remission duration of 1 year or longer.
Exclusion Criteria:
1. Hemoglobin greater than or equal to 10 g/dL.
2. Patients with prior treatment with epoetin alfa or any investigational forms of erythropoietin within the previous 3 months.
3. Patients with known hypersensitivity to mammalian-cell derived products or to human albumin.
4. Uncontrolled hypertension
5. History of thrombotic vascular event.
6. Pregnant or lactating women.
7. Anemia due to factors other than cancer, deficiencies of B12, folate, or iron (only with concurrent treatment of these deficiencies).
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT01099202
Study Brief:
Protocol Section:
NCT01099202